In a bid to bolster its oncology pipeline, Genentech, a member of the Roche Group, has agreed to acquire Regor Therapeutics’ portfolio of next-generation CDK inhibitors for the treatment of breast cancer. The deal, which involves a US$850 M upfront payment, will provide Genentech access to RGT-419B which is the only CDK4 inhibitor with single agent efficacy in refractory ER+/HER2- breast cancer. This agreement marks a major move by Roche to push itself into the HR-positive breast cancer space, which represents around 70% of all breast cancer diagnoses.